The DOI matches its Crossref record; 161 of the 162 references it cites were found in a registry or an index.
Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer
Open accessAbstract
Radiotherapy is an important component of current treatment options for colorectal cancer (CRC). It is either applied as neoadjuvant radiotherapy to improve local disease control in rectal cancers or for the treatment of localized metastatic lesions of CRC. DNA double-strand breaks (DSBs) are the major critical lesions contributing to ionizing radiation (IR)-induced cell death. However, CRC stem cells promote radioresistance and tumor cell survival through activating cell-cycle checkpoints to trigger the DNA damage response (DDR) and DNA repair after exposure to IR. A promising strategy to overcome radioresistance is to target the DDR and DNA repair pathways with drugs that inhibit activated cell-cycle checkpoint proteins, thereby improving the sensitivity of CRC cells to radiotherapy. In this review, we focus on the preclinical studies and advances in clinical trials of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related kinase (ATR), checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2), WEE1 and poly (ADP-ribose) polymerase 1 (PARP1) kinase inhibitors in CRC. Importantly, we also discuss the selective radiosensitization of CRC cells provided by synthetic lethality of these inhibitors and the potential for widening the therapeutic window by targeting the DDR and DNA repair pathways in combination with radiotherapy and immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Radiotherapy (RT) causes DNA damage, and DDR inhibitors selectively mediate G2 checkpoint inhibition, allowing cells with unrepaired DNA to prematurely enter into mitosis, ultimately leading to mitotic catastrophe. DNA damage induces the release of damage-associated molecular pattern (DAMP) molecules. For example, HMGB1 is released into the extracellular environment and then mediates potent pro-inflammatory effects by binding to its downstream receptors such as Toll-like receptors (TLR) and receptors for advanced glycation end products (RAGE) to stimulate efficient processing and cross-presentation of tumor antigens from dying cells. Naive T cells differentiate into tumor-specific CD8+ T cells in response to type I interferon (IFN), leading to activation of anti-tumor immune responses and increased immunogenic cell death. On the other hand, DDR inhibition and mitotic death contribute to the formation of micronuclei, which is detected by cyclic GMP-AMP synthase (cGAS) and stimulate production of type I IFN as well as other inflammatory cytokines via the STING pathway, thereby triggering anti-tumor immune responses by CD8+ T cells. For the nomenclature of early cell death, regulated cell death, immunogenic cell death and mitotic catastrophe, please see the review by Galluzzi et al. [74].](https://figures.cochat.ai/paper-figures/fbee64940d46476c8736c03e7bf7f4d5/targeting-the-dna-damage-response-and-dna-repair-pathways-to-enhance-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defective cell cycle checkpoints allow CRC cells to bypass damage-induced arrest and proceed through the cell cycle with damaged DNA [50].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, PARP inhibitors have also shown efficacy when used in combination with DNA-damaging agents such as chemotherapy and radiotherapy [50,134].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, various studies indicate that DDR inhibitors can sensitize CRC cells to the anticancer effects of chemotherapy and radiotherapy [50].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Global patterns and trends in colorectal cancer incidence and mortality
Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017) · Gut · doi:10.1136/gutjnl-2015-310912 · Cited by 5,228
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597 · cited 1×
“The 5-year survival rate is >90% for patients with localized CRC but declines sharply to 11–15% for patients suffering from metastatic CRC (mCRC) [3].”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421 · cited 1×
“In addition, depending on the genotype of the tumor and its location, antibodies targeting the vascular endothelial growth factor (such as bevacizumab) or epidermal growth factor receptor (such as cetuximab) are added to the chemotherapy regimen [4,5].”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · cited 2×
“In recent years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have been shown to be effective in mCRC patients with DNA repair defects such as deficient mismatch repair (dMMR) or MSI-H CRC [144].”
BackgroundThe Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883 · cited 1×
“Drug resistance is driven by multiple factors, including increased drug efflux, overexpression of proteins related to DNA repair and suppression of proteins engaged in the apoptotic process [142].”
BackgroundNon-homologous DNA end joining and alternative pathways to double-strand break repair
Chang, H. H. Y., Pannunzio, N. R., Adachi, N., & Lieber, M. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.48 · Cited by 1,757 · cited 1×
“The Ku70/Ku80 heterodimer recognizes DSBs and recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) by binding to damaged DNA, which further activates a set of endonucleases and exonucleases such as Artemis, the major enzyme for processing damaged DNA ends [46,47].”
BackgroundDNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514 · cited 1×
“The DDR signaling pathway is made up of a series of reactions with distinct sets of proteins specialized for certain types of damage, which may be classified as sensors, transducers and effectors [16].”
BackgroundDNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189 · cited 1×
“The non-overlapping toxicity of DDR inhibitors and immunotherapy makes the combination of these drugs with radiotherapy also highly attractive [61,158].”
BackgroundTargeting immunogenic cell death in cancer
Ahmed, A., & Tait, S. W. G. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12851 · Cited by 930 · cited 1×
“Naive T cells bind to co-stimulatory receptors on dendritic cells and differentiate into tumor-specific CD8+ T cells in response to type I interferon (IFN), leading to activation of anti-tumor immune responses and increased immunogenic cell death (Figure 2) [149].”
BackgroundMicrobiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
The essential kinase ATR: ensuring faithful duplication of a challenging genome
Saldivar, J. C., Cortez, D., & Cimprich, K. A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.67 · Cited by 838 · cited 1×
“As an apical DDR kinase, ATR maintains genome integrity by phosphorylating multiple enzymes at replication forks, mediated by its downstream target CHK1, resulting in cellcycle arrest and activation of DNA repair mechanisms [69,70].”
Backgroundp53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826 · cited 1×
“Notably, the G1 checkpoint is heavily dependent on p53, which plays a crucial function in protecting hereditary stability by prevention of mutations and mediation of tumor inhibition through a strictly controlled network [26].”
BackgroundExploring the role of cancer stem cells in radioresistance
Baumann, M., Krause, M., & Hill, R. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2419 · Cited by 815
Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3039 · Cited by 773 · cited 1×
“In addition, in an experiment with a subcutaneously implanted osmotic pump combined with IR, ABT-888 was found to have a dose-dependent effect in contrast to IR alone in HCT116 xenografts [112].”
ResultSynthetic lethality and cancer
O'Neil, N. J., Bailey, M. L., & Hieter, P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.47 · Cited by 658 · cited 1×
“Synthetic lethality is a phenomenon in which the perturbation of a single gene is tolerable for cell survival, while the simultaneous perturbation of multiple genes, for instance through pre-existing loss-of-function mutations, leads to cell death [102].”
BackgroundStuck in Division or Passing through
Rieder, C. L., & Maiato, H. (2004) · Developmental Cell · doi:10.1016/j.devcel.2004.09.002 · Cited by 657 · cited 1×
“The SAC is activated by malformed or incomplete spindles, and cells that are kept in mitosis by an activated SAC experience apoptosis after extended mitosis [41].”
BackgroundAdoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Cercek, A., Roxburgh, C. S. D., Strombom, P., Smith, J. J., Temple, L. K. F., Nash, G. M., Guillem, J. G., Paty, P. B., Yaeger, R., Stadler, Z. K., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0071 · Cited by 650 · cited 2×
“Currently, for patients with locally advanced rectal cancer, the standard therapy is neoadjuvant chemoradiotherapy followed by surgery [6,7].”
BackgroundDNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645
ATM and ATR as therapeutic targets in cancer
Weber, A. M., & Ryan, A. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.001 · Cited by 635 · cited 1×
“Owing to their ability to trigger cell-cycle arrest and promote DNA repair through their downstream targets, ATM and ATR inhibitors are considered to improve clinical outcomes of tumor treatment in combination with radiotherapy [62].”
BackgroundTargeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618 · cited 1×
“Base damage and SSBs induced by IR are rapidly and efficiently repaired by base excision repair (BER) while DSBs are repaired by two major mechanisms, nonhomologous end-joining (NHEJ) and homologous recombination (HR) [44].”
BackgroundPARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites
Haince, J.-F., McDonald, D., Rodrigue, A., Déry, U., Masson, J.-Y., Hendzel, M. J., & Poirier, G. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706734200 · Cited by 608 · cited 1×
“In response to radiation exposure, PARP1 is rapidly activated and recruited to the damaged DNA, which suggests that combining PARP inhibitors with radiotherapy could produce synergistic effects [107].”
BackgroundIonizing Radiation-Induced DNA Damage, Response, and Repair
Santivasi, W. L., & Xia, F. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5668 · Cited by 593
Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573 · cited 1×
“In addition, depending on the genotype of the tumor and its location, antibodies targeting the vascular endothelial growth factor (such as bevacizumab) or epidermal growth factor receptor (such as cetuximab) are added to the chemotherapy regimen [4,5].”
BackgroundTheelen, W. S. M. E., Chen, D., Verma, V., Hobbs, B. P., Peulen, H. M. U., Aerts, J. G. J. V., Bahce, I., Niemeijer, A. L. N., Chang, J. Y., de Groot, P. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30391-x · Cited by 564 · cited 1×
“No new safety issues were identified, which provided promising clinical value for the combination of immunotherapy and radiotherapy in CRC, although the optimal immunogenic radiation dose and fractionation regimens remain to be explored [150].”
BackgroundHirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · cited 2×
“Under a fractionated radiotherapy regimen, LoVo xenografts showed a tumor growth delay of 19 days, which increased to 37 days in combination with a low dose of AG14361, whereas AG14361 alone failed to retard tumor growth [110].”
BackgroundRadiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463 · cited 1×
“Several recent ongoing trials (NCT04535024, NCT03101475, NCT03507699) combine immunotherapy with radiotherapy to test the ability to increase the immunogenic cell death in CRC [151].”
BackgroundCHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455 · cited 1×
“When DSBs are recognized by ATM, CHK2 is phosphorylated by ATM at the residue Thr68 and subsequently promotes cell-cycle arrest and DNA repair or apoptosis through phosphorylating its downstream targets, which is faster than transcriptional activation of p21 by p53 [76].”
BackgroundPreclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441
Zhao, Y., Thomas, H. D., Batey, M. A., Cowell, I. G., Richardson, C. J., Griffin, R. J., Calvert, A. H., Newell, D. R., Smith, G. C. M., & Curtin, N. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4275 · Cited by 445 · cited 1×
“NU7441 not only extended the IR-induced G2/M-phase arrest, but also significantly retarded the disappearance of γH2AX foci, indicating that NU7441 markedly delayed the IR-induced DSBs repair [96].”
BackgroundSingle-strand interruptions in replicating chromosomes cause double-strand breaks
Kuzminov, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131009198 · Cited by 406 · cited 1×
“BER inhibition results in unrepaired SSBs, which are converted to DSBs upon encountering replication forks [104].”
BackgroundHarley, M. E., Allan, L. A., Sanderson, H. S., & Clarke, P. R. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.112 · Cited by 353 · cited 1×
“Furthermore, extended activity of the cyclin B/CDK1 complex has been shown to cause degradation of the anti-apoptotic protein Mcl1, resulting in caspase-dependent death in cells with spindle malformations [43].”
BackgroundRadiation as an immunological adjuvant: current evidence on dose and fractionation
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 332
Fok, J. H. L., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12836-9 · Cited by 331 · cited 1×
“AZD7648, a highly selective inhibitor of DNA-PKcs, has been demonstrated in a preclinical study to act as a potent sensitizer of IR-induced DNA damage, thereby promoting tumor cell growth inhibition and apoptosis [143].”
BackgroundForced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Zheng, J., Mo, J., Zhu, T., Zhuo, W., Yi, Y., Hu, S., Yin, J., Zhang, W., Zhou, H., & Liu, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01250-1 · Cited by 326 · cited 1×
“Micronuclei and mtDNA are detected by cyclic GMP-AMP synthase (cGAS) and stimulate production of type I IFN as well as other inflammatory cytokines via the STING pathway, thereby triggering anti-tumor immune responses by CD8+ T cells (Figure 2) [155,156].”
BackgroundDNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322 · cited 1×
“Cell-cycle checkpoints can be activated during the G1- to S-phase transition, S phase and G2- to M-phase transition as a response to DNA damage (Figure 1) [23].”
BackgroundDo, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322 · cited 1×
“NCT01748825 Do [128] I Advanced solid tumors, including CRC Adavosertib (AZD1775, MK-1775) 2 NA 225 mg twice/day 56.”
BackgroundPAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair
Ochi, T., Blackford, A. N., Coates, J., Jhujh, S., Mehmood, S., Tamura, N., Travers, J., Wu, Q., Draviam, V. M., Robinson, C. V., et al. (2015) · Science · doi:10.1126/science.1261971 · Cited by 322
The role of PARP in DNA repair and its therapeutic exploitation
Javle, M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320 · cited 2×
“PARP1 is the best-studied PARP enzyme and plays a key role in repairing DNA damage, as well as regulating chromatin decondensation and cell-cycle arrest [55,100].”
BackgroundA WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Ghelli Luserna di Rorà, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00959-2 · Cited by 314 · cited 2×
“WEE1 phosphorylates CDK1 at Tyr15 of its catalytic subunit, whereas PKMYT1 phosphorylates CDK1 both at the residues Tyr15 and Thr14 resulting in its inactivation [38].”
BackgroundAn intrinsic S/G 2 checkpoint enforced by ATR
Saldivar, J. C., Hamperl, S., Bocek, M. J., Chung, M., Bass, T. E., Cisneros-Soberanis, F., Samejima, K., Xie, L., Paulson, J. R., Earnshaw, W. C., et al. (2018) · Science · doi:10.1126/science.aap9346 · Cited by 308 · cited 1×
“When cells undergo DNA damage in the S phase, stalled replication forks, DSBs, SSBs and ICLs can all trigger temporary S-phase arrest to block further replication [34,35].”
BackgroundCancer Stem Cells and Radioresistance: DNA Repair and Beyond
Schulz, A., Meyer, F., Dubrovska, A., & Borgmann, K. (2019) · Cancers · doi:10.3390/cancers11060862 · Cited by 303 · cited 1×
“Differentiated non-CSCs tumor cells commonly undergo apoptosis after radiation, while colorectal CSCs may evade radiationinduced cell death by a variety of mechanisms, including altering the DNA damage response (DDR) and DNA repair pathways [12,13].”
BackgroundPoly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3
Beck, C., Robert, I., Reina-San-Martin, B., Schreiber, V., & Dantzer, F. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.07.003 · Cited by 302 · cited 1×
“Additionally, PARP1 inhibition and BER depletion contribute to the accumulation of SSBs in the S phase, which ultimately generate DSBs after replication fork collapse [57].”
BackgroundMir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294 · cited 1×
“Indeed, although most anti-cancer treatment strategies aim at causing cell-cycle arrest, the inhibition of WEE1 kinase might release arrested cells with unrepaired damage into mitosis, leading to mitotic catastrophe (Figure 2) [84].”
BackgroundATR: a master conductor of cellular responses to DNA replication stress
Flynn, R. L., & Zou, L. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.005 · Cited by 290 · cited 1×
“As an apical DDR kinase, ATR maintains genome integrity by phosphorylating multiple enzymes at replication forks, mediated by its downstream target CHK1, resulting in cellcycle arrest and activation of DNA repair mechanisms [69,70].”
BackgroundMicrosatellite instability in colorectal cancer
IACOPETTA, B., GRIEU, F., & AMANUEL, B. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01335.x · Cited by 289
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review
Liu, K., Zheng, M., Lu, R., Du, J., Zhao, Q., Li, Z., Li, Y., & Zhang, S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01304-w · Cited by 287
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G., Brown, J., Lau, A., Pratt, G., et al. (2016) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 276 · cited 1×
“ATR inhibition affects the function of DNA damage checkpoints and selectively causes the accumulation of DNA damage in TP53-deficient cells, allowing cells with unrepaired DNA to prematurely enter into mitosis and ultimately leading to mitotic catastrophe (Figure 2) [71,72].”
BackgroundLeijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 264 · cited 1×
“WEE1 NCT00648648 Leijen [127] I Advanced solid tumors, including CRC Adavosertib (AZD1775, MK-1775) + gemcitabine + cisplatin or carboplatin 15 1/15 (6.”
BackgroundIntegrating Old and New Paradigms of G1/S Control
Rubin, S. M., Sage, J., & Skotheim, J. M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.08.020 · Cited by 264 · cited 1×
“Subsequently, cyclin E further binds CDK2 to produce cyclin E/CDK2 complex, which continues to phosphorylate pRB and increase the activity of the S phase in a positive feedback loop to facilitate the G1 to S transition [24,25].”
BackgroundKummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259 · cited 1×
“NCT00553189 Kummar [133] I Solid tumors (including CRC) and lymphomas Veliparib (ABT-888) + topotecan 5 0/5 (0.”
BackgroundYap, T. A., O’Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J., Tunariu, N., Perez-Lopez, R., Rodrigues, D. N., Riisnaes, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02404 · Cited by 251 · cited 1×
“NCT02157792 Yap [118] I Advanced solid tumors, including CRC Berzosertib (M6620, VX-970) ± carboplatin 11 NA 90 mg/m 2 30.”
BackgroundMolecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways
Morgan, M. A., & Lawrence, T. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3229 · Cited by 250
Mechanism of p53 stabilization by ATM after DNA damage
Cheng, Q., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10556 · Cited by 248 · cited 1×
“First, BRCA1 is phosphorylated by ATM at the Ser1423 and Ser1524 sites, and subsequent activation of ATM by BRCA1 phosphorylation causes p53 to be phosphorylated at the Ser15 site, decreasing its binding to MDM2, thus stabilizing p53 expression at the post-transcriptional level [29,30].”
BackgroundMK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
Bridges, K. A., Hirai, H., Buser, C. A., Brooks, C., Liu, H., Buchholz, T. A., Molkentine, J. M., Mason, K. A., & Meyn, R. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0650 · Cited by 237
Phosphorylation of Caspase-9 by CDK1/Cyclin B1 Protects Mitotic Cells against Apoptosis
Allan, L. A., & Clarke, P. R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.019 · Cited by 237 · cited 1×
“rylated and activated after prolonged mitotic arrest [42].”
BackgroundHirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237 · cited 1×
“MK-1775 not only inhibited the phosphorylation of CDK1 at the Tyr15 site, but also abolished the DNA damage checkpoint induced by 5-FU treatment and led to premature mitotic entry through induction of histone H3 phosphorylation [90].”
BackgroundThe Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer
Storozynsky, Q., & Hitt, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228877 · Cited by 228 · cited 1×
“Micronuclei and mtDNA are detected by cyclic GMP-AMP synthase (cGAS) and stimulate production of type I IFN as well as other inflammatory cytokines via the STING pathway, thereby triggering anti-tumor immune responses by CD8+ T cells (Figure 2) [155,156].”
BackgroundRegulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases
Schmidt, M., Rohe, A., Platzer, C., Najjar, A., Erdmann, F., & Sippl, W. (2017) · Molecules · doi:10.3390/molecules22122045 · Cited by 208 · cited 1×
“In the normal cell cycle, and after DNA damage has been repaired, WEE1 is phosphorylated by polo-like kinase 1 and subsequently degraded through the ubiquitin proteome system enabling the G2 to M transition [39].”
BackgroundIliakis, G., Murmann, T., & Soni, A. (2015) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2015.07.001 · Cited by 199 · cited 1×
“Finally, PARP1 is involved in the alternative end-joining (alt-EJ) pathway, which acts as a backup to NHEJ and HR but is much more error-prone [58].”
BackgroundVendetti, F. P., Karukonda, P., Clump, D. A., Teo, T., Lalonde, R., Nugent, K., Ballew, M., Kiesel, B. F., Beumer, J. H., Sarkar, S. N., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96519 · Cited by 198 · cited 1×
“This finding raised the exciting possibility that ATR inhibitors monotherapy could potentiate the cytotoxic effects of radiation while enhancing CD8+ T cell-dependent anti-tumor activity following radiation, resulting in a durable anti-tumor immune response [159].”
BackgroundCuneo, K. C., Morgan, M. A., Sahai, V., Schipper, M. J., Parsels, L. A., Parsels, J. D., Devasia, T., Al-Hawaray, M., Cho, C. S., Nathan, H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00730 · Cited by 195 · cited 1×
“A phase I trial in pancreatic cancer reported a significantly increased OS using the AZD1775 in combination with radiotherapy and gemcitabine compared to AZD1775 alone [140].”
BackgroundSausville, E., LoRusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., Azad, N., Cosgrove, D., Knight, R., Barker, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2380-5 · Cited by 192 · cited 1×
“NCT00413686 Sausville [124] I US patients with advanced solid tumors, including CRC AZD7762 ± gemcitabine 11 NA 30 mg/m 2 69.”
BackgroundThe role of homologous recombination in radiation-induced double-strand break repair
Jeggo, P. A., Geuting, V., & Löbrich, M. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.019 · Cited by 185 · cited 1×
“The half-lives of NHEJ and HR are 5–30 min and 2–5 h, respectively, which represent the quick and slow components of DSBs repair [45].”
BackgroundMaloisel, L., Fabre, F., & Gangloff, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01651-07 · Cited by 174 · cited 1×
“Using the sister chromatid sequence as a template, Pol δ synthesizes error-free DNA and a ligase closes the nick at the freshly extended DNA strand ends [53,54].”
BackgroundTargeting radiation-resistant hypoxic tumour cells through ATR inhibition
Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., McKenna, W. G., & Hammond, E. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.265 · Cited by 170 · cited 3×
“Notably, VE-821 significantly sensitized CRC cells to radiation-induced cell killing under both normal and hypoxic conditions [73].”
BackgroundInfluentialReality CHEK: Understanding the biology and clinical potential of CHK1
Neizer‐Ashun, F., & Bhattacharya, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.016 · Cited by 167 · cited 1×
“Moreover, CHK1 modulates the S-phase checkpoint through facilitating the degradation of CDC25A phosphatase, the activity of which is critical for the removal of suppressive phosphate groups of CDK4 and CDK2 kinases and ensuring cell-cycle progression [22].”
BackgroundThe Enigmatic Function of PARP1: From PARylation Activity to PAR Readers
Kamaletdinova, T., Fanaei-Kahrani, Z., & Wang, Z.-Q. (2019) · Cells · doi:10.3390/cells8121625 · Cited by 164 · cited 1×
“PARP1 is the best-studied PARP enzyme and plays a key role in repairing DNA damage, as well as regulating chromatin decondensation and cell-cycle arrest [55,100].”
BackgroundBatey, M. A., Zhao, Y., Kyle, S., Richardson, C., Slade, A., Martin, N. M. B., Lau, A., Newell, D. R., & Curtin, N. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0707 · Cited by 164 · cited 1×
“Another novel ATM inhibitor KU59403 with enhanced potency and specificity against ATM radiosensitized CRC cell lines independent of TP53 status, providing important preclinical data to support the clinical development of ATM inhibitors in the future [67].”
BackgroundMicrosatellite instability in colorectal cancer.
de’Angelis, G. L., Bottarelli, L., Azzoni, C., de’Angelis, N., Leandro, G., Mario, F. D., Gaiani, F., & Negri, F. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89i9-s.7960 · Cited by 163
DNA-PKcs: A Multi-Faceted Player in DNA Damage Response
Yue, X., Bai, C., Xie, D., Ma, T., & Zhou, P.-K. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.607428 · Cited by 160 · cited 1×
“DNA-PKcs, consisting of 4128 amino acids, is also a member of the PIKKs family and a key enzyme participating in the NHEJ repair pathway [92].”
BackgroundMechanisms of replication fork protection: a safeguard for genome stability
Errico, A., & Costanzo, V. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.655374 · Cited by 159 · cited 1×
“When cells undergo DNA damage in the S phase, stalled replication forks, DSBs, SSBs and ICLs can all trigger temporary S-phase arrest to block further replication [34,35].”
BackgroundPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
Hong, D., Infante, J., Janku, F., Jones, S., Nguyen, L. M., Burris, H. A., Naing, A., Bauer, T. M., Piha-Paul, S., Johnson, F. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5788 · Cited by 159 · cited 1×
“NCT01115790 Hong [121] I Advanced cancer, including CRC Prexasertib (LY2606368) 9 NA 40 mg/m2; 105 mg/m2 88.”
BackgroundSamol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 158 · cited 1×
“NCT00516438 Samol [136] I Advanced solid tumors, including CRC Olaparib (AZD-2281) + topotecan 8 0/8 (0.”
BackgroundAltering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting
Biau, J., Chautard, E., Verrelle, P., & Dutreix, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01009 · Cited by 157 · cited 1×
“For example, BER is the primary repair pathway for SSBs in response to IR-induced oxidative damage [103].”
BackgroundMitchell, J. B., Choudhuri, R., Fabre, K. M., Sowers, A. L., Citrin, D. E., Zabludoff, S., & Cook, J. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3277 · Cited by 149 · cited 1×
“In a study of CRC (HT29) xenografts, AZD7762 combined with radiation significantly delayed tumor growth in comparison to radiation alone, suggesting that AZD7762 could enhance radiosensitivity in vivo [82].”
BackgroundATM’s Role in the Repair of DNA Double-Strand Breaks
Shibata, A., & Jeggo, P. A. (2021) · Genes · doi:10.3390/genes12091370 · Cited by 147 · cited 1×
“DSBs are quickly sensed by the Mre11–Rad50–Nbs1 (MRN) complex, which then interacts with chromatin, followed by promoting the activation of ataxia telangiectasia mutated (ATM) kinase through rapid autophosphorylation at the Ser1981 site [17].”
BackgroundReplication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response
Ragu, S., Matos-Rodrigues, G. E., & López, B. S. (2020) · Genes · doi:10.3390/genes11040409 · Cited by 142
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Oh, M., McBride, A., Yun, S., Bhattacharjee, S., Slack, M. K., Martin, J. R., Jeter, J., & Abraham, I. L. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy148 · Cited by 140 · cited 1×
“Germline mutations in BRCA are currently on the rise as a risk factor for CRC due to the significantly increased risk of early-onset CRC in BRCA mutation carriers [99]; therefore, YU238259 may have significant clinical potential as a new radiosensitizing agent in BRCA2-negative CRC patients.”
BackgroundSelective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics
Chen, Z., Xiao, Z., Gu, W., Xue, J., Bui, M. H., Kovar, P. J., Li, G., Wang, G., Tao, Z., Tong, Y., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22198 · Cited by 139
Middleton, M. R., Dean, E. J., Evans, T. R. J., Shapiro, G. I., Pollard, J. R., Hendriks, B. S., Falk, M., Díaz-Padilla, I., & Plummer, R. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01405-x · Cited by 134 · cited 1×
“ATR NCT02157792 Middleton [116] I Advanced solid tumors, including CRC Berzosertib (M6620, VX-970) + gemcitabne ± cisplatin 22 NA NA 79.”
BackgroundSeligmann, J. F., Fisher, D. J., Brown, L. C., Adams, R. A., Graham, J., Quirke, P., Richman, S. D., Butler, R., Domingo, E., Blake, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01435 · Cited by 124 · cited 1×
“AZD1775, the only WEE1 inhibitor currently in clinical development, significantly improved progression-free survival (PFS) compared with active monitoring in mCRC with TP53 and RAS mutations in a phase II trial and demonstrated its potential as a well-tolerated treatment for mCRC with TP53/RAS mutations [139].”
MethodNosho, K., Yamamoto, H., Mikami, M., Taniguchi, H., Takahashi, T., Adachi, Y., Imamura, A., Imai, K., & Shinomura, Y. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.061 · Cited by 120 · cited 1×
“3%) at the early stages of CRC (65 adenomas and 26 submucosal carcinomas, respectively) [105].”
BackgroundHomologous Recombination and the Formation of Complex Genomic Rearrangements
Piazza, A., & Heyer, W. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.10.006 · Cited by 119 · cited 1×
“RAD51 replaces RPA with the help of BRCA2, thereby mediating the matching of the homologous sequence to the damaged sequence in the sister chromatid or homologous chromosome and DNA strand invasion [52].”
BackgroundATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Jette, N., Kumar, M., Radhamani, S., Arthur, G., Goutam, S., Yip, S., Kolinsky, M. P., Williams, G. J., Bose, P., & Lees‐Miller, S. P. (2020) · Cancers · doi:10.3390/cancers12030687 · Cited by 116
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
Huang, F., Goyal, N., Sullivan, K., Hanamshet, K., Patel, M., Mazina, O. M., Wang, C. X., An, W. F., Spoonamore, J. E., Metkar, S. R., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw087 · Cited by 116 · cited 1×
“HR begins with the excision of 5′ DNA ends, followed by the binding of RPA to single-strand 3′ DNA ends [51].”
BackgroundCDK-Independent and PCNA-Dependent Functions of p21 in DNA Replication
Mansilla, S. F., De La Vega, M. B., Calzetta, N. L., Siri, S. O., & Gottifredi, V. (2020) · Genes · doi:10.3390/genes11060593 · Cited by 114 · cited 1×
“Stable p53 stimulates transcription of the downstream gene CDKN1A coding for the CDK inhibitor p21, which binds and further represses the cyclin E/CDK2 and cyclin A/CDK2 complexes, leading to the G1/S arrest [31,32].”
BackgroundWEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry
Elbæk, C. R., Petrosius, V., & Sørensen, C. S. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111694 · Cited by 112 · cited 1×
“The activated WEE1 inactivates the cyclin B/CDK1 complex by phosphorylating CDK1, thereby mediating S- and G2-phase arrest [83].”
BackgroundCapp, J., Boudsocq, F., Bertrand, P., Laroche‐Clary, A., Pourquier, P., López, B. S., Cazaux, C., Hoffmann, J.-S., & Canitrot, Y. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl380 · Cited by 111 · cited 1×
“In NHEJ, DNA Pol μ and Pol λ fill the DNA gaps before ligation [49,50].”
BackgroundSeto, T., Esaki, T., Hirai, F., Arita, S., Nosaki, K., Makiyama, A., Kometani, T., Fujimoto, C., Hamatake, M., Takeoka, H., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2234-6 · Cited by 104 · cited 1×
“NCT00937664 Seto [125] I Japanese patients with advanced solid tumors, including CRC AZD7762 ± gemcitabine 5 NA 21 mg/m 2 60.”
BackgroundCombination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo
Lin, C., Yu, Y., Zhao, H.-G., Yang, A., Yan, H., & Cui, Y. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.10.023 · Cited by 104 · cited 1×
“In addition, quercetin, a major antioxidant flavonoid, sensitized a CRC cell line to IR in vitro and in vivo, which was associated with a significantly extended presence of IR-induced γH2AX foci and prolonged DNA repair by inhibiting ATM kinase activation [68].”
BackgroundManic, G., Signore, M., Sistigu, A., Russo, G., Corradi, F., Siteni, S., Musella, M., Vitale, S., De Angelis, M. L., Pallocca, M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-312623 · Cited by 98 · cited 2×
“Notably, this was also the case in cells carrying KRAS mutations, a subgroup of CRC that is especially difficult to target and treat [81].”
BackgroundIsmail, I. H., Mårtensson, S., Moshinsky, D. J., Rice, A. G., Tang, C., Howlett, A. R., McMahon, G., & Hammarsten, O. (2003) · Oncogene · doi:10.1038/sj.onc.1207303 · Cited by 94 · cited 1×
“DNA-PKcs specific inhibitors are particularly attractive in combination with radiotherapy as an efficient strategy to improve the prognosis of tumor patients and have been developed as radiosensitizers [93,94].”
BackgroundShapiro, G. I., Wesolowski, R., Devoe, C., Lord, S., Pollard, J. R., Hendriks, B. S., Falk, M., Díaz-Padilla, I., Plummer, R., & Yap, T. A. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01406-w · Cited by 89 · cited 1×
“NCT02157792 Shapiro [117] I Advanced solid tumors, including CRC Berzosertib (M6620, VX-970) + cisplatin 5 NA NA 70.”
BackgroundStern, M. C., Conti, D. V., Siegmund, K. D., Corral, R., Yuan, J., Koh, W., & Yu, M. C. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0268 · Cited by 88 · cited 1×
“Furthermore, a significant correlation between single nucleotide polymorphisms (SNPs) in the PARP1 gene and CRC risk was identified in a candidate-SNP study of 1176 healthy controls and 310 patients (180 colon and 130 rectal cancer) from the Singapore Chinese Health Study [106].”
BackgroundRegulation of MDM2 E3 Ligase Activity by Phosphorylation after DNA Damage
Cheng, Q., Cross, B. L., Li, B., Chen, L., Li, Z., & Chen, J. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05553-11 · Cited by 85 · cited 1×
“First, BRCA1 is phosphorylated by ATM at the Ser1423 and Ser1524 sites, and subsequent activation of ATM by BRCA1 phosphorylation causes p53 to be phosphorylated at the Ser15 site, decreasing its binding to MDM2, thus stabilizing p53 expression at the post-transcriptional level [29,30].”
BackgroundLeichman, L., Groshen, S. G., O’Neil, B. H., Messersmith, W. A., Berlin, J. D., Chan, E. W., Leichman, C. G., Cohen, S. J., Cohen, D. J., Lenz, H., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0319 · Cited by 83 · cited 2×
“Results of this trial showed that olaparib was clinically inactive in both MSI-H and MSS mCRC patients [134].”
BackgroundResultTargeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
Bukhari, A. B., Chan, G. K. T., & Gamper, A. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.828684 · Cited by 83 · cited 1×
“However, subsequent studies suggested that raddiosensitization may occur independently of TP53 status although it may require a deregulated G1/S checkpoint [88].”
BackgroundKwok, M., Davies, N., Agathanggelou, A., Smith, E., Petermann, E., Yates, E., Brown, J. S., Lau, A., & Stanković, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60373-7 · Cited by 82 · cited 1×
“ATR inhibition affects the function of DNA damage checkpoints and selectively causes the accumulation of DNA damage in TP53-deficient cells, allowing cells with unrepaired DNA to prematurely enter into mitosis and ultimately leading to mitotic catastrophe (Figure 2) [71,72].”
BackgroundItaliano, A., Infante, J. R., Shapiro, G. I., Moore, K. N., LoRusso, P. M., Hamilton, E. P., Cousin, S., Toulmonde, M., Postel-Vinay, S. C., Tolaney, S. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy076 · Cited by 81 · cited 1×
“NCT01564251 Italiano [123] I Refractory solid tumors (including CRC), or lymphoma GDC-575 (ARRY-575; RG7741) 4 NA 60 mg/m 2 49 a”
BackgroundWilloughby, C. E., Jiang, Y., Thomas, H. D., Willmore, E., Kyle, S., Wittner, A., Phillips, N., Zhao, Y., Tudhope, S. J., Prendergast, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127483 · Cited by 80 · cited 1×
“DNA-PKcs specific inhibitors are particularly attractive in combination with radiotherapy as an efficient strategy to improve the prognosis of tumor patients and have been developed as radiosensitizers [93,94].”
BackgroundThe fork and the kinase: A DNA replication tale from a CHK1 perspective
Besteiro, M. A. G., & Gottifredi, V. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.10.003 · Cited by 77 · cited 1×
“In response to SSBs, CHK1 is phosphorylated by ATR, thereby facilitating the initiation of cell-cycle checkpoints in the S and G2/M phases and DNA damage repair [75].”
BackgroundCzito, B. G., Deming, D. A., Jameson, G., Mulcahy, M. F., Vaghefi, H., Dudley, M. W., Holen, K. D., DeLuca, A., Mittapalli, R. K., Munasinghe, W. P., et al. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30012-2 · Cited by 76 · cited 3×
“PARP NCT01589419 Czito [115] Ib Locally advanced rectal cancer Veliparib (ABT-888) + capecitabine + RT MTD, RP2D 32 9/32 (28.”
BackgroundResultInfluentialClinical Development of Novel Drug–Radiotherapy Combinations
Ahmad, S. S., Crittenden, M. R., Tran, P. T., Kluetz, P. G., Blumenthal, G. M., Bulbeck, H., Baird, R. D., Williams, K. J., Illidge, T., Hahn, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2466 · Cited by 75 · cited 1×
“The non-overlapping toxicity of DDR inhibitors and immunotherapy makes the combination of these drugs with radiotherapy also highly attractive [61,158].”
BackgroundLi, J., Holzschu, D. L., & Sugiyama, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222241110 · Cited by 74 · cited 1×
“Using the sister chromatid sequence as a template, Pol δ synthesizes error-free DNA and a ligase closes the nick at the freshly extended DNA strand ends [53,54].”
BackgroundMatthews, T. P., Jones, A. M., & Collins, I. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.788496 · Cited by 73 · cited 1×
“CHK2 has a structurally similar active site to CHK1, there is close crosstalk between them and their activation and substrates also overlap significantly [77].”
BackgroundTao, Y., Leteur, C., Yang, C., Ping, Z., Castedo, M., Pierré, A., Golsteyn, R. M., Bourhis, J., Kroemer, G., & Deutsch, É. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8203 · Cited by 71 · cited 1×
“Importantly, these results were not associated with TP53 mutation status [80].”
BackgroundPishvaian, M. J., Slack, R. S., Jiang, W., He, A. R., Hwang, J. J., Hankin, A., Dorsch‐Vogel, K., Kukadiya, D., Weiner, L. M., Marshall, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31309 · Cited by 69 · cited 1×
“NCT01051596 Pishvaian [135] II Heavily pretreated metastatic CRC Veliparib (ABT-888) + temozolomide 75 2/75 (2.”
BackgroundAndrade, P., Martín, M. J., Juárez, R., de Saro, F. J. L., & Blanco, L. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0908492106 · Cited by 67 · cited 1×
“In NHEJ, DNA Pol μ and Pol λ fill the DNA gaps before ligation [49,50].”
BackgroundPoggio, F. B., Bruzzone, M., Ceppi, M., Conte, B., Martel, S., Maurer, C., Tagliamento, M., Viglietti, G., Mastro, L. D., de Azambuja, E., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000361 · Cited by 66 · cited 1×
“This has been beneficial in the management of BRCA1/BRCA2-deficient breast and ovarian cancers and can significantly improve patient prognosis as monotherapy or in combination with conventional therapies [101].”
BackgroundStructure of the intact ATM/Tel1 kinase
Wang, X., Chu, H., Lv, M., Zhang, Z., Qiu, S., Liu, H., Shen, X., Wang, W., & Cai, G. (2016) · Nature Communications · doi:10.1038/ncomms11655 · Cited by 66 · cited 1×
“ATM remains inactive in the form of a homodimer under normal conditions; however, in the presence of IR-induced DSBs, ATM is recruited and activated through intermolecular autophosphorylation and homodimer dissociation, which then triggers the DNA damage checkpoint and facilitates the damaged DNA repair through activa…”
BackgroundShelton, J. W., Waxweiler, T. V., Landry, J., Gao, H., Xu, Y., Wang, L., El-Rayes, B., & Shu, H.-K. G. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.015 · Cited by 62
Microsatellite Instability in Colorectal Cancer
Ruszkiewicz, A. R., & Jass, J. R. (2004) · Pathology Case Reviews · doi:10.1097/01.pcr.0000132991.85133.ef · Cited by 61
Gorbunova, V. A., Beck, J. T., Hofheinz, R., Alfonso, P. G., Nechaeva, M., Gracián, A. C., Mangel, L., Élez, E., Deming, D. A., Ramanathan, R. K., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0343-z · Cited by 58 · cited 1×
“NCT02305758 Gorbunova [132] II Untreated metastatic CRC Veliparib (ABT-888) + FOLFIRI ± bevacizumab 65 37/65 (57) NA 59.”
BackgroundActivation of ATR-related protein kinase upon DNA damage recognition
Ma, M., Rodriguez, A., & Sugimoto, K. (2019) · Current Genetics · doi:10.1007/s00294-019-01039-w · Cited by 58 · cited 1×
“Unlike DSBs, SSBs are detected by the Rad9–Hus1–Rad1 complex, which activates ataxia telangiectasia and Rad3-related kinase (ATR) in collaboration with Rad17, Rfc2, Rfc3, Rfc4 and Rfc5 [20].”
BackgroundChen, E. X., Jonker, D. J., Siu, L. L., McKeever, K., Keller, D., Wells, J., Hagerman, L., & Seymour, L. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0351-x · Cited by 56 · cited 1×
“NCT00535353 Chen [131] I Advanced or metastatic CRC Olaparib (AZD-2281) + irinotecan 25 0/25 (0.”
BackgroundWaqar, S. N., Robinson, C. G., Olszanski, A. J., Spira, A. I., Hackmaster, M., Lucas, L., Sponton, L., Jin, H., Hering, U., Cronier, D. M., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01216-8 · Cited by 55 · cited 3×
“All patients reported at least one TRAE, and two of them suffered severe adverse events (SAEs), which were not considered to be related to M3541 [114].”
BackgroundInfluentialStukenberg, P. T., & Burke, D. J. (2015) · Chromosoma · doi:10.1007/s00412-015-0515-z · Cited by 52 · cited 1×
“In mitosis, proper division of the replicated genome is ensured by a mechanism known as the spindle assembly checkpoint (SAC), which delays the degradation of cyclin B and the anaphase inhibitor securin by prohibiting the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C) until all chromosomal pairs have bi…”
BackgroundRadiosensitization by PARP inhibition to proton beam irradiation in cancer cells
Hirai, T., Saito, S., Fujimori, H., Matsushita, K., Nishio, T., Okayasu, R., & Masutani, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.062 · Cited by 51 · cited 1×
“The DNA repair activity of PARP1 has been targeted in combination with radiotherapy based on the finding that inhibition of PARP1 may increase the radiosensitivity in cancer cells [108,109].”
BackgroundDual function of MDM2 and MDMX toward the tumor suppressors p53 and RB
Hernández‐Monge, J., Rousset-Roman, A. B., Medina‐Medina, I., & Olivares‐Illana, V. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.120 · Cited by 50 · cited 1×
“Under physiological circumstances, p53 protein is maintained at low level by tight binding to the murine double minute 2 (MDM2), a p53-specific E3 ubiquitin ligase, resulting in its proteasomal degradation [27].”
BackgroundRadiation-induced DNA damage response and resistance in colorectal cancer stem-like cells
Anuja, K., Chowdhury, A. R., Saha, A., Roy, S., Rath, A. K., Kar, M., & Banerjee, B. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1580401 · Cited by 50 · cited 1×
“For example, radioresistant CSCs derived from colorectal HCT116 cells showed enhanced survival associated with a significantly reduced number of phosphorylated histone γH2AX repair foci and increased mRNA and protein expression levels of ERCC1, a subunit of the repair endonuclease, XPF-ERRC1 [14].”
BackgroundYap, T. A., Krebs, M., Postel-Vinay, S. C., Bang, Y., El-Khoueiry, A. B., Abida, W. M., Harrington, K. J., Sundar, R., Carter, L., Álvarez, E. C., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32607-7 · Cited by 48 · cited 1×
“Early data showed that the combination therapy of AZD6738 and olaparib exhibited overlapping toxicity profiles, mostly myelosuppression, yet the non-overlapping toxicity of AZD6738 and durvalumab makes the combination of DDR inhibitors and immunotherapy attractive for CRC treatment [157].”
BackgroundSong, Y., Huang, J., Liang, D., Hu, Y., Mao, B., Li, Q., Sun, H., Yang, Y., Zhang, J., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.549777 · Cited by 44
Luo, C., Wang, J., Hung, W.-C., Peng, G., Tsai, Y.-L., Chang, T., Chai, C., Lin, C., & Pan, M. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.03.002 · Cited by 43 · cited 1×
“Differentiated non-CSCs tumor cells commonly undergo apoptosis after radiation, while colorectal CSCs may evade radiationinduced cell death by a variety of mechanisms, including altering the DNA damage response (DDR) and DNA repair pathways [12,13].”
BackgroundCDC25A pathway toward tumorigenesis: Molecular targets of CDC25A in cell‐cycle regulation
Sadeghi, H., Golalipour, M., Yamchi, A., Farazmandfar, T., & Shahbazi, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26838 · Cited by 43 · cited 1×
“ATR and ATM are activated by DNA damage and promote the proteasomal degradation of CDC25A via CHK1 and CHK2, respectively, thereby suppressing the activity of cyclin A/CDK2 complex and preventing the further progression of the S phase [21,36].”
BackgroundActivation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition
Ditano, J. P., Sakurikar, N., & Eastman, A. R. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1938813 · Cited by 42 · cited 2×
“kinase (CDK) 2 and cyclin A/CDK2 complexes, thereby blocking cells in the G1 phase from entering the S phase [21].”
BackgroundGiovannini, S., Weller, M.-C., Repmann, S., Moch, H., & Jiricny, J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz624 · Cited by 40 · cited 1×
“The synthetic lethal interaction may be attributed to the HR deficiency caused by BRCA1/2 mutations, which in turn further impairs DNA repair through PARP1 inhibition, consequently killing tumor cells through a dual effect [56].”
BackgroundChen, S., Zhou, Q., Guo, Z., Wang, Y., Wang, L., Liu, X., Lü, M., Ju, L., Xiao, Y., & Wang, X. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14878 · Cited by 40 · cited 1×
“Stable p53 stimulates transcription of the downstream gene CDKN1A coding for the CDK inhibitor p21, which binds and further represses the cyclin E/CDK2 and cyclin A/CDK2 complexes, leading to the G1/S arrest [31,32].”
BackgroundYin, Y., Shen, Q., Tao, R., Chang, W., Li, R., Xie, G., Liu, W., Zhang, P., & Tao, K. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8230 · Cited by 36 · cited 4×
“Several preclinical studies of the WEE1 inhibitor adavosertib (AZD1775 or MK-1775) indicated that adavosertib eliminated the G2-phase checkpoint and radiosensitized TP53deficient cells due to mitotic lethality [85–87].”
BackgroundInfluentialCell cycle involvement in cancer therapy; WEE1 kinase, a potential target as therapeutic strategy
Vakili‐Samiani, S., Khanghah, O. J., Gholipour, E., Najafi, F., Zeinalzadeh, E., Samadi, P., Sarvarian, P., Pourvahdani, S., Kelaye, S. K., Hamblin, M. R., et al. (2022) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2022.111776 · Cited by 36 · cited 1×
“Therefore, several novel WEE1 inhibitors are undergoing preclinical tests in various cancer types [89].”
BackgroundHo, A. L., Bendell, J. C., Cleary, J. M., Schwartz, G. K., Burris, H. A., Oakes, P., Agbo, F., Barker, P. N., Senderowicz, A. M., & Shapiro, G. I. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3033 · Cited by 35 · cited 1×
“NCT00473616 Ho [126] I Advanced solid tumors, including CRC AZD7762 + irinotecan 29 NA 96 mg/m 2 10.”
BackgroundDNA Damage Repair Inhibitors—Combination Therapies
Smith, G., Alholm, Z., Coleman, R. L., & Monk, B. J. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000561 · Cited by 35 · cited 2×
“PARP, ATR NCT02723864 Smith [137] I Refractory solid tumors, including CRC veliparib (ABT-888) + berzosertib (M6620, VX-970) + cisplatin 3 NA NA 35.”
BackgroundMembrane receptor signaling and control of DNA repair after exposure to ionizing radiation
Toulany, M., & Rodemann, H. P. (2010) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0038-1626525 · Cited by 34
The combination of olaparib and camptothecin for effective radiosensitization
Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-62 · Cited by 33 · cited 1×
“The topoisomerase I inhibitor camptothecin enhanced the radiosensitizing effect of the PARP inhibitor olaparib, resulting in increased numbers of γH2AX foci and G2/M arrest [113].”
BackgroundComparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
Kleiman, L. B., Krebs, A. M., Kim, S. Y., Hong, T. S., & Haigis, K. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082982 · Cited by 33 · cited 4×
“A study identified AZD7762 as a CHK1 inhibitor with equivalent potency against CHK2 in a set of four rectal cancer cell lines.”
BackgroundInfluentialBerlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J. L., Kang, Y., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0003-3 · Cited by 32 · cited 1×
“PARP NCT02033551 Berlin [130] I Advanced solid tumors, including CRC Veliparib (ABT-888) + FOLFIRI 10 2/10 (20.”
BackgroundBendell, J. C., Bischoff, H. G., Hwang, J. J., Reinhardt, H. C., Zander, T., Wang, X., Hynes, S. M., Pitou, C., Campbell, R. M., Iversen, P. W., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00873-6 · Cited by 32 · cited 1×
“CHK1 NCT02860780 Bendell [119] I Advanced/metastatic cancer, including CRC Prexasertib (LY2606368) + ralimetinib 9 NA 105 mg/m 2 33.”
Herskind, C., Wenz, F. K., & Giordano, F. A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00147 · Cited by 32
Self-citationThe Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors
van Bijsterveldt, L., Durley, S. C., Maughan, T., & Humphrey, T. C. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3358 · Cited by 31 · cited 1×
“However, responses often differ between individual tumors, and some major issues remain with the clinical application of these inhibitors in combination with radiotherapy [141].”
BackgroundPeng, G., CAO, R.-B., LI, Y.-H., Zou, Z., Huang, J., & Ding, Q. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2463 · Cited by 30 · cited 1×
“Subsequently, cyclin E further binds CDK2 to produce cyclin E/CDK2 complex, which continues to phosphorylate pRB and increase the activity of the S phase in a positive feedback loop to facilitate the G1 to S transition [24,25].”
BackgroundA first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Plummer, E. R., Kristeleit, R. S., Cojocaru, E., Haris, N. M., Carter, L., Jones, R. H., Blagden, S. P., Evans, T. R. J., Arkenau, H., Sarker, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3094 · Cited by 29 · cited 1×
“NCT02797964 Plummer [122] I/II Advanced solid tumors (including CRC), non-hodgkin’s lymphoma SRA737 (CCT245737) 32 NA 1000 mg/day 44.”
Moore, K. N., Hong, D. S., Patel, M. R., Pant, S., Ulahannan, S. V., Jones, S. F., Meric‐Bernstam, F., Wang, J. S.-Z., Aljumaily, R. M., Hamilton, E. P., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00835-0 · Cited by 28 · cited 1×
“NCT02124148 Moore [120] Ib Advanced/metastatic cancer, including CRC Prexasertib (LY2606368) + cetuximab 41 2/41 (4.”
BackgroundVormoor, B. J., Schlosser, Y. T., Blair, H., Sharma, A. B., Wilkinson, S., Newell, D. R., & Curtin, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.21300 · Cited by 27 · cited 1×
“The DNA repair activity of PARP1 has been targeted in combination with radiotherapy based on the finding that inhibition of PARP1 may increase the radiosensitivity in cancer cells [108,109].”
BackgroundLi, S.-J., Liang, X., Li, H., Li, W., Zhou, L., Chen, H., Ye, S.-G., Yu, D., & Cui, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3795 · Cited by 23 · cited 1×
“The G1/S checkpoint is activated via the ATM/p53/p21 pathway by DNA damage in the G1 phase [28].”
BackgroundInhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer
Smithson, M. G., Irwin, R. K., Williams, G., McLeod, M. C., Choi, E. K., Ganguly, A., Pepple, A., Cho, C. S., Willey, C. D., Leopold, J., et al. (2022) · Neoplasia · doi:10.1016/j.neo.2022.01.004 · Cited by 22 · cited 1×
“Mice with CT26 tumors treated with M3814 in combination with 5-FU and radiation exhibited significantly higher clinical complete response (cCR) but no difference in average tumor size or pCR, which may be due to increased activity of other repair mechanisms that impair the therapeutic effect [97].”
BackgroundSun, X., Yang, C., Liu, H., Wang, Q., Wu, S., Li, X., Xie, T., Brinkman, K. L., Teh, B. S., Butler, E. B., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.092 · Cited by 22 · cited 1×
“BTW3 significantly prolonged IR-induced formation of γH2AX foci and delayed DNA damage repair in human colon cancer RKO cell lines, sensitizing the cells to IR [95].”
BackgroundDownregulated Ku70 and ATM associated to poor prognosis in colorectal cancer among Chinese patients
Lu, Y., Lu, Y., & Gao, J. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s67814 · Cited by 21 · cited 1×
“Somatic ATM mutations are identified in about 20% of CRC patients, usually occurring in the functional domain as heterozygous variants, and loss of ATM expression is also linked to advanced TNM stage and poor 5-year overall survival (OS) in CRC patients [64,65].”
BackgroundEvolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer
Patel, P. A. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283441a63 · Cited by 19 · cited 2×
“Currently, for patients with locally advanced rectal cancer, the standard therapy is neoadjuvant chemoradiotherapy followed by surgery [6,7].”
BackgroundStachelek, G. C., Peterson-Roth, E., Liu, Y., Fernandez, R. J., Pike, L., Qian, J. M., Abriola, L., Hoyer, D., Hungerford, W. M., Merkel, J., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0036 · Cited by 19 · cited 14×
“Other important NHEJ proteins including X-ray cross-complementing protein 4 (XRCC4), ligase IV and XRCC4-like factor (XLF) are recruited and collectively facilitate the alignment and ligation of DNA ends [48].”
BackgroundInfluentialA potential new role of ATM inhibitor in radiotherapy: suppressing ionizing Radiation-Activated EGFR
Tang, S., Li, Z., Yang, L., Shen, L., & Wang, Y. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1707325 · Cited by 19 · cited 8×
“NU7441 not only extended the IR-induced G2/M-phase arrest, but also significantly retarded the disappearance of γH2AX foci, indicating that NU7441 markedly delayed the IR-induced DSBs repair [96].”
BackgroundInfluentialGarcía‐Santisteban, I., Llopis, A., Krenning, L., Vallejo-Rodríguez, J., van den Broek, B., Zubiaga, A. M., & Medema, R. H. (2021) · BMC Biology · doi:10.1186/s12915-021-00965-x · Cited by 16 · cited 1×
“ATM triggers signal transduction by activating the phosphorylation of hundreds of substrates, including the transcription factor p53 (TP53) and the checkpoint kinase 2 (CHK2), inducing cell-cycle arrest and apoptosis [18].”
BackgroundFuchß, T., Grädler, U., Schiemann, K., Kühn, D., Kubas, H., Dahmen, H., Zimmermann, A., Zenke, F. T., & Blaukat, A. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3500 · Cited by 15 · cited 1×
“Actually, the development of a second-generation ATM inhibitor M4076 is underway and the drug has entered the clinical study (NCT04882917) [138].”
BackgroundCohen, D. J., Grabocka, E., Bar‐Sagi, D., Godin, R. E., & Leichman, L. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.tps3627 · Cited by 6 · cited 1×
“NCT02906059 Cohen [129] Ib KRAS, NRAS or BRAF mutated metastatic CRC Adavosertib (AZD1775, MK-1775) + irinotecan 7 NA NA NA”
BackgroundRouhani, M. (2019) · Journal of Biological Physics · doi:10.1007/s10867-018-9519-2 · Cited by 5 · cited 1×
“The Ku70/Ku80 heterodimer recognizes DSBs and recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) by binding to damaged DNA, which further activates a set of endonucleases and exonucleases such as Artemis, the major enzyme for processing damaged DNA ends [46,47].”
BackgroundPhenotypic Analysis of ATM Protein Kinase in DNA Double-Strand Break Formation and Repair
Mian, E., & Wiesmüller, L. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6955-5_23 · Cited by 3 · cited 1×
“Additionally, ATM enables the phosphorylation of histone H2AX to produce γH2AX as well, which is essential for the coordination of cell-cycle checkpoint activation and DSBs repair [19].”
Background
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Defective cell cycle checkpoints allow CRC cells to bypass damage-induced arrest and proceed through the cell cycle with damaged DNA [50].”
New Horizons in Lung Cancer Management Through ATR/CHK1 Pathway Modulation
Thapa, R., Afzal, O., Bhat, A. A., Goyal, A., Altamimi, A. S. A., Almalki, W. H., Alzarea, A. I., Kazmi, I. A., Singh, S. K., Dua, K., et al. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0164 · Cited by 78
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S. (2023) · MedComm · doi:10.1002/mco2.288 · Cited by 62
PARP inhibitors combined with radiotherapy: are we ready?
Sun, C., Chu, A., Song, R., Liu, S., Chai, T., Wang, X., & Liu, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1234973 · Cited by 52
Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy
Wang, X., Zhang, H., XinZhang, & Liu, Y. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00628-3 · Cited by 49
“The interplay between the DNA damage response and STING signaling within the tumor cells is critical in the formation of an inflammatory microenvironment that is governed by RT [67, 68].”
Background
Metadata
- Authors
- Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Herskind, Carsten
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-10-05
- Volume
- 14
- Issue
- 19
- Pages
- 4874
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9561988
- OpenAlex
- W4303621977
- Cited by
- 62
- References
- 162
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 12 · 2023: 10
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- China Scholarship Council (202106070027, 404521405)
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (202106070027, 404521405)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Keywords
- colorectal cancer, radiosensitization, DNA damage response, DNA repair, radioresistance (biology), DNA double-strand breaks, cell cycle checkpoints, DNA-PKcs inhibitor, ATM inhibitors, ATR inhibitors, CHK1 inhibitor, CHK2 inhibitors, WEE1 inhibitor, PARP-1 inhibitors, synthetic lethality, combination immunotherapy, rectal cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.